{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:30:41Z","timestamp":1793831441857,"version":"4.6.1"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"\n Importance<\/jats:title>\n It is unclear whether and the extent to which subclinical myocardial injury or stress coexisting with prediabetes is associated with the risk of heart failure (HF).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the joint associations of prediabetes and subclinical myocardial injury or stress with incident HF risk.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This post hoc prospective cohort study analyzed data from the Systolic Blood Pressure Intervention Trial (SPRINT). Two analytic samples were used: (1) adults with hypertension without diabetes or prior HF for the baseline biomarkers analysis and (2) participants with biomarker measurements at both baseline and 12 months for the longitudinal biomarkers\u2019 change. Prediabetes was defined as a fasting plasma glucose level of 100 to 125 mg\/dL. Subclinical myocardial injury was defined as a high-sensitivity cardiac troponin I (hs-cTnI) level of 6 ng\/L or higher in men and 4 ng\/L or higher in women and subclinical myocardial stress defined as an N-terminal pro\u2013B-type natriuretic peptide (NT-proBNP) level of 125 pg\/mL or higher. A 25% or greater increase in any biomarker concentration from baseline to 12 months defined longitudinal change. Data were analyzed between January 1 and May 31, 2025.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was adjudicated incident HF. Cox proportional hazards models were used to estimate hazard ratios (HRs) for HF across joint categories of prediabetes and biomarker elevation.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 8234 participants (mean [SD] age, 68 [9] years; 37.1% women), 3271 (39.7%) had prediabetes, 2942 (35.7%) had subclinical myocardial injury, and 3593 (43.6%) had subclinical myocardial stress. Over a median follow-up of 3.2 years (IQR, 2.8-3.8 years), 122 participants developed HF. Compared with normoglycemia and no myocardial injury, those with both prediabetes and injury had the highest HF risk (HR, 4.20; 95% CI, 2.31-7.63); similar findings were observed for myocardial stress (HR, 5.20; 95% CI, 2.52-10.70). In the longitudinal analysis (median follow-up, 2.3 years [IQR, 1.9-2-8 years]), 7449 participants with both prediabetes and a 25% or greater increase in hs-cTnI or NT-proBNP level had the highest risk of HF (for hs-cTnI: HR, 3.05; 95% CI, 1.58-5.88; for NT-proBNP: HR, 2.39; 95% CI, 1.28-4.46).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n These findings suggest that among adults with hypertension, prediabetes in combination with subclinical myocardial injury or stress is associated with a significantly elevated risk for HF. These findings support the integration of glycemic status and cardiac biomarkers profiling to improve HF risk stratification and guide prevention.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2025.4927","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:00:46Z","timestamp":1768406446000},"page":"281","source":"Crossref","is-referenced-by-count":6,"title":["Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension"],"prefix":"10.1001","volume":"11","author":[{"given":"Arnaud D.","family":"Kaze","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Banner-University Medical Center Phoenix, The University of Arizona College of Medicine, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Juraschek","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordana B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Banner-University Medical Center Phoenix, The University of Arizona College of Medicine, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiadi E.","family":"Ndumele","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas"},{"name":"Center for Cardiometabolic Disease Prevention, Department of Medicine, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarrett D.","family":"Berry","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas at Tyler School of Medicine, Tyler"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin B.","family":"Echouffo-Tcheugui","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland"},{"name":"Welch Prevention Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"hbr250022r1","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000001303","article-title":"2025 Heart Disease and Stroke Statistics: a report of US and global data from the American Heart Association.","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"issue":"3","key":"hbr250022r2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1161\/CIRCULATIONAHA.108.845792","article-title":"The progression of hypertensive heart disease.","volume":"123","author":"Drazner","year":"2011","journal-title":"Circulation"},{"key":"hbr250022r3","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11125","author":"Gonz\u00e1lez","year":"2018","journal-title":"Hypertension"},{"issue":"11","key":"hbr250022r4","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.numecd.2018.07.005","article-title":"Diabetes mellitus, blood glucose and the risk of heart failure: a systematic review and meta-analysis of prospective studies.","volume":"28","author":"Aune","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"hbr250022r5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jchf.2014.08.004","article-title":"Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure.","volume":"3","author":"Dei Cas","year":"2015","journal-title":"JACC Heart Fail"},{"issue":"8","key":"hbr250022r7","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/dom.14388","article-title":"Prediabetes and the risk of heart failure: a meta-analysis.","volume":"23","author":"Cai","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"hbr250022r8","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1373\/clinchem.2013.203638","article-title":"Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk\u2013the atherosclerosis risk in communities study.","volume":"59","author":"Nambi","year":"2013","journal-title":"Clin Chem"},{"issue":"23","key":"hbr250022r9","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1161\/CIRCULATIONAHA.124.069735","article-title":"NT-proBNP and cardiac troponin I, but not cardiac troponin T, are associated with 7-year changes in cardiac structure and function in older adults: the ARIC study.","volume":"150","author":"Myhre","year":"2024","journal-title":"Circulation"},{"issue":"18","key":"hbr250022r10","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"hbr250022r11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jacc.2011.10.875","article-title":"Chronic hyperglycemia and subclinical myocardial injury.","volume":"59","author":"Rubin","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hbr250022r12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1177\/1740774514537404","article-title":"The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).","volume":"11","author":"Ambrosius","year":"2014","journal-title":"Clin Trials"},{"issue":"22","key":"hbr250022r13","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control.","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"hbr250022r14","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamacardio.2021.3187","article-title":"Associations of high-sensitivity troponin and natriuretic peptide levels with outcomes after intensive blood pressure lowering: findings from the SPRINT randomized clinical trial.","volume":"6","author":"Berry","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"2","key":"hbr250022r15","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/clinchem\/hvad209","article-title":"High-sensitivity cardiac troponins I and T and cardiovascular outcomes: findings from the Systolic Blood Pressure Intervention Trial (SPRINT).","volume":"70","author":"Jia","year":"2024","journal-title":"Clin Chem"},{"key":"hbr250022r6","unstructured":"Oktay? AA, Paul? TK, Koch? CA, Lavie? CJ. Diabetes, cardiomyopathy, and heart failure. In: Feingold KR, Anawalt B, Blackman MR, et al, eds. Endotext. Last Update: September 26, 2023. Accessed May 5, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560257\/"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2843810\/jamacardiology_kaze_2026_br_250022_1773061347.8003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:00:57Z","timestamp":1773241257000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2843810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.4927","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}